📊 CTXR Key Takeaways
Investment Thesis
Citius Pharmaceuticals exhibits severe operational distress with negative operating income of -$9.0M on just $3.9M in revenue, indicating the company is burning cash at an unsustainable rate. Operating losses have resulted in negative free cash flow of -$13.0M annually, with only $7.7M in cash reserves and a current ratio of 0.99x signaling imminent liquidity concerns. The company demonstrates no meaningful revenue growth (0.0% YoY) while operating at massive losses, suggesting fundamental business model challenges.
CTXR Strengths
- High gross margin of 80.0% indicates strong unit economics when sales occur
- Minimal debt load with debt-to-equity ratio of 0.01x provides some financial flexibility
- Substantial asset base of $140.4M relative to liabilities suggests underlying asset value
CTXR Risks
- Negative operating margin of -228.7% demonstrates severe operational inefficiency and inability to cover operating expenses
- Monthly cash burn of approximately $1.1M with only $7.7M in cash represents less than 7 months of runway at current burn rate
- Current ratio of 0.99x and quick ratio of 0.40x indicate critical liquidity stress and potential inability to meet near-term obligations
- Stagnant revenue growth of 0.0% YoY combined with expanding losses suggests loss of market traction or failed commercialization
- Negative free cash flow of -$13.0M annually indicates the company requires external capital to survive
- No insider purchases in last 90 days may reflect lack of management confidence
Key Metrics to Watch
- Monthly cash burn rate and months of cash runway remaining
- Quarterly revenue trajectory and pipeline advancement milestones
- Achievement of operating expense reduction or major revenue inflection points
- Capital raising activities and dilution impacts
- Current and quick ratios for liquidity deterioration
CTXR Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CTXR Profitability Ratios
CTXR vs Healthcare Sector
How Citius Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CTXR Balance Sheet & Liquidity
CTXR 5-Year Financial Trend
5-Year Trend Summary: Citius Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.97 indicates the company is currently unprofitable.
CTXR Growth Metrics (YoY)
CTXR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.9M | -$9.4M | $-0.38 |
| Q3 2022 | $90.0K | -$4.1M | $-0.05 |
| Q2 2022 | $90.0K | -$4.1M | N/A |
| Q1 2022 | $90.0K | -$8.1M | N/A |
| Q3 2021 | $90.0K | -$4.1M | N/A |
| Q2 2021 | $90.0K | -$4.1M | N/A |
| Q1 2021 | $90.0K | -$4.3M | N/A |
| Q3 2020 | $90.0K | -$3.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CTXR Capital Allocation
CTXR SEC Filings
Access official SEC EDGAR filings for Citius Pharmaceuticals, Inc. (CIK: 0001506251)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTXR
What is the AI rating for CTXR?
Citius Pharmaceuticals, Inc. (CTXR) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTXR's key strengths?
High gross margin of 80.0% indicates strong unit economics when sales occur. Minimal debt load with debt-to-equity ratio of 0.01x provides some financial flexibility.
What are the risks of investing in CTXR?
Negative operating margin of -228.7% demonstrates severe operational inefficiency and inability to cover operating expenses. Monthly cash burn of approximately $1.1M with only $7.7M in cash represents less than 7 months of runway at current burn rate.
What is CTXR's revenue and growth?
Citius Pharmaceuticals, Inc. reported revenue of $3.9M.
Does CTXR pay dividends?
Citius Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find CTXR SEC filings?
Official SEC filings for Citius Pharmaceuticals, Inc. (CIK: 0001506251) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTXR's EPS?
Citius Pharmaceuticals, Inc. has a diluted EPS of $-0.38.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.